SSY Group Limited announced that it has received approvals for the production and registration of Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administration of China. Classified as type 4 chemical drugs, both dosage forms have successfully passed the consistency evaluation, reinforcing the Group's commitment to high-quality pharmaceutical standards.
Levamlodipine Besilate Tablets are indicated for the treatment of hypertension, helping to lower elevated blood pressure and reduce cardiovascular risk. The medication can be used either as a standalone therapy or in combination with other antihypertensive agents, offering flexible options for effective blood pressure management.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.